CATX Form 3: Joel Sendek (CFO) files initial statement with no shares

Rhea-AI Filing Summary

Joel Sendek, serving as Chief Financial Officer and a director of Perspective Therapeutics, Inc. (CATX), filed an initial Form 3 reporting the 09/04/2025 event date. The filing states that the reporting person does not beneficially own any securities of the issuer. The form references Exhibit 24 (Power of Attorney) and was signed via attorney-in-fact on 09/05/2025.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sendek Joel

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/04/2025

3. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

1. No securities are benefically owned. 2. Exhibit 24 - Power of Attorney.

No securities are beneficially owned.

	/s/ Joel Sendek by Chris Nenno, as Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joel Sendek report on the Form 3 for Perspective Therapeutics (CATX)?

The Form 3 reports that Joel Sendek (CFO and director) does not beneficially own any securities of Perspective Therapeutics as of the 09/04/2025 event date.

What is the filing date and signature information on the Form 3?

The document shows the event date 09/04/2025 and was signed by attorney-in-fact Chris Nenno on behalf of Joel Sendek on 09/05/2025.

Does the Form 3 include any derivative or non-derivative securities holdings?

No. The filing explicitly states that no securities are beneficially owned, and both Table I and Table II contain no reported holdings.

Is there a power of attorney referenced in the Form 3 for CATX?

Yes. The filing references Exhibit 24, which is the Power of Attorney used to sign the form.

What position does Joel Sendek hold at Perspective Therapeutics according to the filing?

The Form 3 lists Joel Sendek as a Director and as an Officer with the title Chief Financial Officer.